NASDAQ:BCLI - Brainstorm Cell Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $3.88 +0.03 (+0.78 %) (As of 02/22/2019 06:00 AM ET)Previous Close$3.85Today's Range$3.85 - $3.9452-Week Range$2.92 - $5.35Volume37,508 shsAverage Volume66,093 shsMarket Capitalization$80.35 millionP/E RatioN/ADividend YieldN/ABeta1.32 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient's own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival. It is developing NurOwn for various neurodegenerative diseases, including its lead indication, which is in Phase III clinical trial for the treatment of amyotrophic lateral sclerosis, as well as in preclinical trial for the treatment of multiple sclerosis, Parkinson's disease, Huntington's disease, and autism spectrum disorder. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in New York, New York. Receive BCLI News and Ratings via Email Sign-up to receive the latest news and ratings for BCLI and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BCLI Previous Symbol CUSIPN/A CIK1137883 Webwww.brainstorm-cell.com Phone201-488-0460Debt Debt-to-Equity RatioN/A Current Ratio3.33 Quick Ratio3.33Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.31 per share Price / Book12.52Profitability EPS (Most Recent Fiscal Year)($0.26) Net Income$-4,950,000.00 Net MarginsN/A Return on Equity-101.86% Return on Assets-59.62%Miscellaneous Employees24 Outstanding Shares20,710,000Market Cap$80.35 million Next Earnings Date3/14/2019 (Estimated) OptionableOptionable Brainstorm Cell Therapeutics (NASDAQ:BCLI) Frequently Asked Questions What is Brainstorm Cell Therapeutics' stock symbol? Brainstorm Cell Therapeutics trades on the NASDAQ under the ticker symbol "BCLI." How were Brainstorm Cell Therapeutics' earnings last quarter? Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) issued its quarterly earnings results on Monday, October, 29th. The biotechnology company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.10) by $0.05. View Brainstorm Cell Therapeutics' Earnings History. When is Brainstorm Cell Therapeutics' next earnings date? Brainstorm Cell Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 14th 2019. View Earnings Estimates for Brainstorm Cell Therapeutics. What price target have analysts set for BCLI? 3 brokers have issued 12 month price objectives for Brainstorm Cell Therapeutics' stock. Their predictions range from $9.00 to $11.00. On average, they anticipate Brainstorm Cell Therapeutics' stock price to reach $10.00 in the next year. This suggests a possible upside of 157.7% from the stock's current price. View Analyst Price Targets for Brainstorm Cell Therapeutics. What is the consensus analysts' recommendation for Brainstorm Cell Therapeutics? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Brainstorm Cell Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Brainstorm Cell Therapeutics. What are Wall Street analysts saying about Brainstorm Cell Therapeutics stock? Here are some recent quotes from research analysts about Brainstorm Cell Therapeutics stock: 1. Maxim Group analysts commented, "BrainStorm announced that the Israel Patent Office has granted it a new patent for NurOwn. With this patent, the company continues to expand its intellectual property (IP) portfolio for NurOwn building on its strategy to eventually have a global patent portfolio which would provide access to patients worldwide." (1/22/2019) 2. HC Wainwright analysts commented, "We note that Right to Try" laws exist in 38 states, today: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Idaho, Illinois, Indiana, Iowa, Kentucky, Louisiana, Maine, Maryland, Michigan, Minnesota, Mississippi, Missouri, Montana, Nevada, New Hampshire, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, South Dakota, Tennessee, Texas, Utah, Virginia, West Virginia, Washington and Wyoming — but this federal bill would introduce legislation across state lines." (5/29/2018) Has Brainstorm Cell Therapeutics been receiving favorable news coverage? Press coverage about BCLI stock has been trending positive this week, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Brainstorm Cell Therapeutics earned a coverage optimism score of 2.3 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 8.0 out of 10, indicating that recent press coverage is very likely to have an effect on the stock's share price in the near term. Who are some of Brainstorm Cell Therapeutics' key competitors? Some companies that are related to Brainstorm Cell Therapeutics include Solid Biosciences (SLDB), Cellular Biomedicine Group (CBMG), Eiger Biopharmaceuticals (EIGR), Sutro Biopharma (STRO), Adverum Biotechnologies (ADVM), LogicBio Therapeutics (LOGC), ADMA Biologics (ADMA), Compugen (CGEN), La Jolla Pharmaceutical (LJPC), Erytech Pharma (ERYP), Fennec Pharmaceuticals (FENC), Surface Oncology (SURF), Jounce Therapeutics (JNCE), Neon Therapeutics (NTGN) and Allena Pharmaceuticals (ALNA). What other stocks do shareholders of Brainstorm Cell Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Brainstorm Cell Therapeutics investors own include Achaogen (AKAO), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Celldex Therapeutics (CLDX), Alibaba Group (BABA), Zynerba Pharmaceuticals (ZYNE), Novavax (NVAX), Mellanox Technologies (MLNX), Progenics Pharmaceuticals (PGNX) and Adamis Pharmaceuticals (ADMP). Who are Brainstorm Cell Therapeutics' key executives? Brainstorm Cell Therapeutics' management team includes the folowing people: Mr. Chaim Lebovits, Pres & CEO (Age 48)Dr. Ralph Z. Kern, COO & Chief Medical Officer (Age 61)Mr. Uri Yablonka, Exec. VP, Chief Bus. Officer & Director (Age 42)Mr. Arturo O. Araya, Chief Commercial Officer (Age 48)Mr. Eyal Rubin, CFO & Treasurer (Age 44) Who are Brainstorm Cell Therapeutics' major shareholders? Brainstorm Cell Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include ETF Managers Group LLC (0.32%). Company insiders that own Brainstorm Cell Therapeutics stock include Irit Arbel, June Sherie Almenoff, Ralph Dr Kern and Uri Yablonka. View Institutional Ownership Trends for Brainstorm Cell Therapeutics. Which institutional investors are buying Brainstorm Cell Therapeutics stock? BCLI stock was purchased by a variety of institutional investors in the last quarter, including ETF Managers Group LLC. Company insiders that have bought Brainstorm Cell Therapeutics stock in the last two years include Irit Arbel, June Sherie Almenoff, Ralph Dr Kern and Uri Yablonka. View Insider Buying and Selling for Brainstorm Cell Therapeutics. How do I buy shares of Brainstorm Cell Therapeutics? Shares of BCLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Brainstorm Cell Therapeutics' stock price today? One share of BCLI stock can currently be purchased for approximately $3.88. How big of a company is Brainstorm Cell Therapeutics? Brainstorm Cell Therapeutics has a market capitalization of $80.35 million. The biotechnology company earns $-4,950,000.00 in net income (profit) each year or ($0.26) on an earnings per share basis. Brainstorm Cell Therapeutics employs 24 workers across the globe. What is Brainstorm Cell Therapeutics' official website? The official website for Brainstorm Cell Therapeutics is http://www.brainstorm-cell.com. How can I contact Brainstorm Cell Therapeutics? Brainstorm Cell Therapeutics' mailing address is 1325 AVENUE OF AMERICAS 28TH FLOOR, NEW YORK NY, 10019. The biotechnology company can be reached via phone at 201-488-0460 or via email at [email protected] MarketBeat Community Rating for Brainstorm Cell Therapeutics (NASDAQ BCLI)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 192 (Vote Outperform)Underperform Votes: 135 (Vote Underperform)Total Votes: 327MarketBeat's community ratings are surveys of what our community members think about Brainstorm Cell Therapeutics and other stocks. Vote "Outperform" if you believe BCLI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BCLI will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/22/2019 by MarketBeat.com StaffFeatured Article: What is the Book Value of a Share?